Video Series: Current Topics in the Treatment of Advanced PCa

Targeted Agents

Philip Kantoff, MD, Andrew Armstrong, MD, William Oh, MD, and A. Oliver Sartor, MD, discuss advances in treatment of castration-resistant prostate cancer and metastatic castration-resistant prostate cancer, specifically newer hormonal therapies.

Latest Prostate Cancer Features

MRI/US Fusion Improves Prostate Cancer Detection

MRI/US Fusion Improves Prostate Cancer Detection

The approach can help identify suitable candidates for active surveillance, but false positives and cost effectiveness are concerns.

Latest Prostate Cancer News

Multiparametric MRI May Prevent Unnecessary Prostate Biopsies

Multiparametric MRI May Prevent Unnecessary Prostate Biopsies

Using imaging to triage men with elevated PSA might avoid a quarter of unnecessary biopsies, according to a study.

Autologous Urethral Sling Does Not Improve Continence After Prostatectomy

Autologous Urethral Sling Does Not Improve Continence After Prostatectomy

No benefit of autologous urethral sling placement at robotic assisted radical prostatectomy on early return of continence at 6 months.

Prostatic Enlargement Linked to Obesity

Prostatic Enlargement Linked to Obesity

Benign prostatic hyperplasia is more likely to develop among men with larger waist circumference and body mass index and higher leptin levels.

Prostate Cancer Death Rate Fell in the United States

Prostate Cancer Death Rate Fell in the United States

The investigators found that the cancer mortality rate hit its peak in 1991, before beginning a steady slide of roughly 1.5% per year among both men and women through 2014.

No Greater Risk of Bone Metastases With 12-Week Zoledronic Acid

No Greater Risk of Bone Metastases With 12-Week Zoledronic Acid

The proportions of skeletal-related events did not differ significantly between the every 4-week dosing group vs the every 12-week dosing group of bone metastases patients.

Prostate Cancer Risk Lower in Men With Prostate Atrophy

Prostate Cancer Risk Lower in Men With Prostate Atrophy

Prostate atrophy in more cores also was associated with lower risks of low- and high-grade disease.

Significant Prostate Cancer Found in Advanced Bladder Cancer Patients

Significant Prostate Cancer Found in Advanced Bladder Cancer Patients

In a study, 53.1% of patients had concomitant prostate cancer in radical cystectomy specimens.

New Prostate Cancer Grading System Validated

New Prostate Cancer Grading System Validated

Proposed 5-tiered system found to predict the risk of prostate cancer-specific mortality.

Some AS Patients Eligible for Relaxed Prostate Biopsy Schedules

Some AS Patients Eligible for Relaxed Prostate Biopsy Schedules

Patients on active surveillance with stable disease at the time of initial surveillance prostate biopsy may be appropriate candidates for less intensive surveillance prostate biopsy schedules.

Lethal Prostate Cancer Linked to BRCA1/2, ATM Mutations

Lethal Prostate Cancer Linked to BRCA1/2, ATM Mutations

Mutation carrier status was associated with earlier death and among lethal prostate cancer patients (age 67 vs 72 in non-carriers) and shorter survival.

Prostate Cancer AS Patients May Benefit from MRI/Fusion Biopsy

Prostate Cancer AS Patients May Benefit from MRI/Fusion Biopsy

In patients undergoing confirmatory biopsy for active surveillance, MRI can increase detection of clinically significant tumors compared with standard systematic biopsy.

PITX2 Methylation of Prostate Biopsies Aids Risk Assessment

PITX2 Methylation of Prostate Biopsies Aids Risk Assessment

PITX2 methylation was increased in tumor-positive biopsies.

Prostate Cancer Active Surveillance Criteria May Need Updating

Prostate Cancer Active Surveillance Criteria May Need Updating

When MRI-US fusion biopsy is added to the standard 12-core biopsy, the number of men eligible for active surveillance decreases, study finds.

Standard TRUS Prostate Biopsy Needed Despite Negative MRIs

Standard TRUS Prostate Biopsy Needed Despite Negative MRIs

Magnetic resonance imaging of the prostate missed 13% of high-grade cancers that were later found on transrectal ultrasound-guided biopsy.

Radium-223 Reduces Hospital Usage for Skeletal Events

Radium-223 Reduces Hospital Usage for Skeletal Events

CRPC patients treated with radium-223 spent fewer days in the hospital both before and after a skeletal event compared with placebo recipients.

Sign up for free e-Newsletters